Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer

Clinical Oncology

Volumn 20, Issue 6, 2008, Pages 401-416

  Tierney, J F ^a   Vale, C ^a   Symonds, P ^b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Drug therapy; radiotherapy; randomised controlled trials; review; systematic review; uterine cervical neoplasms

Indexed keywords

BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IFOSFAMIDE; MESNA; METHOTREXATE; MITOMYCIN C; PLATINUM; TIRAPAZAMINE; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG TARGETING; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYDROXYUREA; NEOADJUVANT THERAPY; RADIOTHERAPY; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 46149090782     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.04.003     Document Type: Article

References (98)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Arbyn M., Raifu A.O., Autier P., and Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 18 10 (2007) 1708-1715
3. Ries LAG, Harkins D, Krapcho M, et al. SEER cancer statistics review, 1975-2003. National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site; 2006 [accessed March 2008].
4. Eifel P.J., Berek J.S., and Thigpen J.T. Gynecologic cancers. Section 2. Cancer of the cervix, vagina, vulva. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6th edn. (2001), Lippincott-Raven, Philadelphia 1526-1556
5. Symonds R.P., Collingwood M., Kirwan J., et al. Concomitant hydroxurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. Cancer Treat Rev 30 (2004) 405-414
6. Symonds R.P., Collingwood M., Kirwan J., et al. Concomitant hydroxurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. Cochrane Database Syst Rev 1 (2004) CD003918
7. Piver M.S., Barlow J.J., Vongtama V., and Webester J. Hydroxyurea and radiation therapy in advanced cervical cancer. Am J Obstet Gynecol 120 (1974) 969-972
8. Piver M.S., Barlow J.J., Vongtama V., and Blumenson L. Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. Am J Obstet Gynecol 129 (1977) 379-383
9. Hreshchyshyn M.M., Aron B.S., Boronow R.C., Franklin E.W., Shingleton H.M., and Blessing J.A. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 5 (1979) 317-322
10. Piver M., Khalil M., and Emrich L.J. Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIB cervical cancer. J Surg Oncol 42 2 (1989) 120-125
11. Piver M.S., Barlow J.J., Vongtama V., and Blumenson L. Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study. Am J Obstet Gynecol 147 7 (1983) 803-808
12. Piver S.M., Vongtama V., and Emrich L.J. Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stage IIIB cervical cancer. J Surg Oncol 35 (1987) 129-134
13. Madoc-Jones H., Perez C., Camel M., and Jennings F. Preliminary experience in a prospective randomized trial to assess the value of hydroxyurea in addition to conventional radiotherapy in the management of advanced stages of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 6 10 (1980) 1430
14. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
15. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
16. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
17. Whitney C.W., Sause W., Bundy B.N., et al. Randomised comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB--IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
18. Peters WA, Liu PY, Barrett RGW, et al. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III inter group study. Gynecol Oncol 1999;72(3):443.
19. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358 (2001) 781-786
20. Wong L.C., Choo Y.S., Choy D., Sham J.S.T., and Ma H.K. Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol Oncol 35 (1989) 159-163
21. Onishi H., Yagamushi M., Kuriyama K., et al. Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radiotherapy. Cancer J Sci Am 6 (2000) 40-45
22. Lira Puerto V., De la Huerta R., Cortes H., et al. Cisplatin (CDDP) plus radiotherapy (RT) vs radiotherapy alone in locally advanced cervical cancer. Proc Am Soc Clin Oncol 9 (1990) A633
23. Tseng C.-J., Chang C.-T., Lai C.-H., et al. A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the cervix. Gynecol Oncol 66 (1997) 52-58
24. Pearcey R., Brundage M., Drouin P., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20 4 (2002) 966-972
25. Chen H.-W., Fan J.-J., Luo W., et al. A randomized trial of hyperthermo-radiochemotherapy for uterine cervix cancer. Chin J Oncol 24 (1997) 249-251
26. Garipagaoglu M., Kayikcioglu F., Kose M.F., et al. Adding concurrent low dose continuous infusion of cisplatin to radiotherapy in locally advanced cervical carcinoma: a prospective randomized pilot study. Br J Radiol 77 (2004) 581-587
27. Singh T.T., Singh I.Y., Sharma D.T., and Singh N. Role of chemoradiation in advanced cervical cancer. Indian J Cancer 40 3 (2003) 101-107
28. Lanciano R.M., Calkins A., Bundy B.N., et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervical cancer: a Gynecologic Oncology Group study. J Clin Oncol 23 33 (2005) 8289-8295
29. Mitra D., Ghosh B., Kar A., Basu S., Deb A.R., and Sur P.K. Role of chemoradiotherapy in advanced carcinoma cervix. J Indian Med Assoc 104 8 (2006) 432-438
30. Saibish Kumar EP, Lal P, Tiwari A, et al. Chemo-irradiation versus radiotherapy alone in locally advanced carcinoma of the uterine cervix - an ongoing phase III trial. 23rd ESTRO 2004, Amsterdam, Oct 24--27 abstract 673.
31. Cikaric S., Petrovic-Stupar S., Marjanov I., et al. Radiotherapy vs. radiotherapy + chemotherapy of advanced cervical cancer: regression of tumour, early and late sequalaes, relapses of disease and 3 years survival (the third phase). Eur J Cancer (2005) 3(Suppl 2):266 (Poster 924)
32. Peters III W.A., Liu P.Y., Barrett II R.J., et al. Comparative parameters of myelotoxicity in patients treated with simultaneous chemotherapy and radiotherapy or only radiotherapy. J Clin Oncol 18 (2000) 1606-1613
33. Kantardzic N., Beslija S., and Begic D. Comparative parameters of myelotoxicity in patients treated with simultaneous chemotherapy and radiotherapy or only radiotherapy. Med Arh 58 1 (2004) 19-22
34. Eifel P.J., Winter K., Morris M., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of a Radiation Therapy Oncology Group Trial (RTOG) 90-91. J Clin Oncol 22 (2004) 872-880
35. Bulnes R., and Rivera R. Carcinoma Epidermoide del cervix uterino: tratamiento con radiotherapia y quimioterapia asociadas. Prensa Med Argent 73 3 (1986) 100-103
36. Hernandez J.R.A., Rafael de la Huerta S., Canfield F.M., and Orozco A.F. Cáncer cervicouterino. Etapa clínica III. Tratamiento combinado de radioterapia quimioterapia. Ginecol Obstet Mex 59 (1991) 238-242
37. Wong L.C., Ngan A.N.Y., Cheung A.N.Y., Cheng D.K.L., Ng T.Y., and Choy D.T.K. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 17 7 (1999) 2055-2060
38. Lorvidhaya V., Chitapanarux I., Sangruchi S., et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 55 5 (2003) 1226-1232
39. Thomas G., Dembo A., Ackerman I., et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. Gynecol Oncol 69 (1998) 137-145
40. Fernandez DJ, Vidyasagar MS, Rao KK, et al. Synchronous 5-fluorouracil, mitomycin-c and radiation therapy in the treatment of locally advanced carcimoma of the cervix. Proceedings of the 16th Annual Meeting of the Association of Radiation Oncologists of India. Kerala: 1995. p. 97-103.
41. Roberts K.B., Urdaneta N., Vera R., et al. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer (Radiat Oncol Invest) 90 (2000) 206-223
42. Lukka H., Hirte H., Fyles A., et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer - a meta-analysis. Clin Oncol 14 (2002) 203-212
43. Green J., Kirwan J., Tierney J., et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. CD002225.pub2. Cochrane Database Syst Rev 3 (2005) 10.1002/14651858.CD002225.pub2
44. Chalmers I. The Cochrane Collaboration: preparing, maintaining and disseminating systematic reviews of the effects of health care. Ann NY Acad Sci 703 (1993) 156-165
45. Vale C., Tierney J., and Stewart L. Concomitant chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data. Gynecol Oncol 100 2 (2006) 442-443
46. Vale C.L. Concomitant chemoradiation in cervical cancer: a meta-analysis using individual patient data from randomised clinical trials. Available from. www.esgo.org/esgo15/program/session1/asp 15th Annual Meeting of the European Society of Gynaecological Oncology 2007
47. Neoadjuvant Chemotherapy for Cervix Cancer Meta-analysis (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 39 17 (2003) 2470-2486
48. Chauvergne J., Lhomme C., Rohart J., et al. Chimiothérapie néoadjuvante des cancer du col utérin aux stades IIb e III. Résultats éloignés d'un essai randomisé pluricentrique portant sur 151 patients. Bull Cancer (Paris) 80 (1993) 1069-1079
49. Souhami L., Gil R.A., Allan S.E., et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 9 6 (1991) 970-977
50. Tattersall M.H.N., Ramirez C., and Coppleson M. A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs radiotherapy alone in patients with locally advanced cervical cancer. Int J Gynecol Cancer 2 (1992) 244-251
51. Herod J., Burton A., Buxton J., et al. A randomised prospective phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Ann Oncol 11 (2000) 1175-1181
52. Sardi J.E., Giaroli A., Sananes C., et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix. The final results. Gynecol Oncol 67 (1997) 61-69
53. Cárdenas J, Olguín A, Figueroa F, Peña J, Beccerra F, Huizar R. A randomized trial of chemotherapy (CT) followed by radiotherapy (RT) vs radiotherapy alone in stage IIIb cervical carcinoma: preliminary results. Fourth International Congress on Anti-cancer Chemotherapy 1993: 87.
54. Sardi J.E., Sananes C.E., Giaroli A.A., et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Cancer 8 (1998) 441-450
55. Cárdenas J., Olguín A., Figueroa F., Beccerra F., and Huizar R. Randomized neoadjuvant chemotherapy in cervical carcinoma stage IIb. PEC+ RT vs RT. Proc Am Soc Clin Oncol 10 (1991) 189 A620
56. Chiara S., Bruzzone M., Merlini L., et al. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. Am J Clin Oncol 17 4 (1994) 294-297
57. Sardi J., Giaroli A., Sananes C., et al. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic management. Int J Gynecol Cancer 6 (1996) 85-93
58. Sundfor K., Tropé C.G., Högberg T., et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer 77 (1996) 2371-2378
59. Tattersall M.H.N., Lorvidhaya V., Vootiprux V., et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. J Clin Oncol 13 2 (1995) 444-451
60. Kumar L., Grover R., Pokharel Y.H., et al. Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomised studies. Aust N Z J Med 28 (1998) 387-390
61. Symonds R.P., Habeshaw T., Reed N.S., et al. The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. Eur J Cancer 36 (2000) 994-1001
62. Leborgne F., Leborgne J.H., Doldán R., et al. Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial. Int J Radiat Oncol Biol Phys 37 2 (1997) 343-350
63. Tabata T., Takeshima N., Nishida H., Hirai Y., and Hasumi K. A randomized study of primary bleomycin, vincristine, mitomycin and cisplatin (BOMP) chemotherapy followed by radiotherapy versus radiotherapy alone in stage IIIB and IVA squamous cell carcinoma of the cervix. Anticancer Res 23 3C (2003) 2885-2890
64. Khalil A., Shamseddine A., Geara F., Charafeddine M., and Seoud M. Concurrent chemo-radio-therapy for locally advanced cervical cancer: a prospective randomized trial comparing cis-platinum vs paclitaxel. Proc Am Soc Clin Oncol 23 (2005) [abstract 5163]
65. Kamnerdsupaphon P., Chitapanarux I., Sukthomya V., and Lorvidhaya V. The 50-month results of the four non-platinum concurrent chemoradiation regimens for locally advanced cervical cancer. Proc Am Soc Clin Oncol 25 (2007) [abstract 5540]
66. Parmar M.K.B., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
67. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., and Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8 1 (2007) 16
68. Rew D.A., and Wilson G.D. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol 26 (2000) 405-417
69. Bolger B.S., Symonds R.P., Stanton P.D., et al. Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer 74 (1996) 1223-1226
70. Perez C.A., Grigsby P.W., Castro-Vita H., and Lockett M.A. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on the outcome of radiation therapy. Int J Radiat Oncol Biol Phys 32 5 (1995) 1275-1288
71. Kigawa J., Minagawa Y., Ishihara H., Itamochi H., Kanamori Y., and Terawaka N. The role of neoadjuvant intra-arterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer. Am J Clin Oncol 19 3 (1996) 255-259
72. Benedetti-Panici P., Greggi S., Colombo A., et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomised study. J Clin Oncol 20 1 (2002) 179-188
73. Chang T.-C., Lai C.-H., Hong J.-H., et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage Ib and IIA cervical cancer. J Clin Oncol 18 8 (2000) 1740-1747
74. Park S.Y., Kim J.H., Kim B.G., et al. Phase III randomized study of MVC intraarterial (arm 1), or systemic (arm 2) neoadjuvant chemotherapy versus radiation therapy only (arm 3) for stage IIb bulky carcinoma of uterine cervix: preliminary report. Proc Am Soc Clin Oncol 15 (1996) 302 A840
75. Napolitano U., Imperato F., Mossa B., Framarino M.L., Marziani R., and Marzetti L. The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial. Eur J Gynaecol Oncol 24 1 (2003) 51-59
76. Eddy G.L., Bundy B.N., Creasman W.T., et al. Treatment of ('bulky') stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol 106 2 (2007) 362-369
77. Cai H.B., Chen H.Z., and Yin H.H. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res 32 3 (2006) 315-323
78. Katsumata N., Yoshikawa H., Hirakawa T., et al. Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer (JCOG 0102). Proc Am Soc Clin Oncol 24 (2006) [abstract 5013]
79. Eifel P.J., Moughan J., Erickson B., Iarocci T., Grant D., and Owen J. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. Int J Radiat Oncol Biol Phys 60 (2004) 1144-1153
80. Barbera L., Paszat L., Thomas G., et al. The rapid uptake of concurrent chemotherapy for cervix cancer patients treated with curative radiation. Int J Radiat Oncol Biol Phys 64 5 (2006) 1389-1394
81. Gaffney D.K., Du Bois A., Narayan K., et al. Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys 68 (2007) 485-490
82. Pearcey R., Miao Q., Kong W., Zhang-Salomens J., and MacKillop W.J. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population based cohort study. J Clin Oncol 25 17 (2007) 2383-2388
83. Buda A., Fossati R., Colombo N., et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 23 18 (2005) 4137-4145
84. Glynne-Jones R., and Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?. J Clin Oncol 25 33 (2007) 5281-5286
85. Monk B.J., Wang J., Im S., et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 96 (2005) 721-728
86. Dreicer R. Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards. Urol Oncol 25 1 (2007) 72-75
87. Stokes Z., Symonds P., Habeshaw T., et al. Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer. Gynecol Oncol 97 3 (2005) 790-795
88. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 23 21 (2005) 4626-4633
89. Vandenput I., Amant F., Neven P., Berteloot P., Leunen K., and Vergote I. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 17 1 (2007) 83-87
90. Cerciello F., Riesterer O., Sherweif M., Odermatt B., and Ciernik I.F. Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix?. Gynecol Oncol 106 2 (2007) 394-399
91. Bellone S., Frera G., Landolfi G., et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 106 3 (2007) 513-520
92. Kersemaekers A.M., Fleuren G.J., Kenter G.G., et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5 3 (1999) 577-586
93. Kim G.E., Kim Y.B., Cho N.H., et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 10 4 (2004) 1366-1374
94. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
95. Nadler LM, Takvorian T, Botnick L, et al. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed b-cell non-Hodgkin's lymphoma. Lancet 1984;2(8400):427-431.
96. Burstein H.J., Storniolo A.M., Franco S., et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19 6 (2008) 1068-1074
97. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
98. Toms J.R. Cancerstats monograph 2004 (2004), Cancer Research UK, London